Constarium
← Search

Data · dataset · 2026

<p><i>NOXA</i> KO restores cellular viability and decreases apoptosis during <i>MARCH5</i> KO.</p>

Listed in UCL Research Data Repository

<p>A. Workflow of the characterization experiments of the <i>NOXA-MARCHF5</i> double KO (DKO) BC-1 Cas9 cells.

Description

Cells were transduced with a lentivirus encoding the targeting gRNA (SAFE4501 or <i>NOXA</i> g1), an eGFP reporter, and puromycin resistance gene (puro<sup>R</sup>). After selection and confirmation of <i>NOXA</i> KO by Western blotting (panel B), these cells were transduced with a second lentivirus encoding another targeting gRNA (g<i>AAVS1</i>, <i>MARCHF5</i> g2 or g3) and the hygromycin resistance gene (hyg<sup>R</sup>).

After 7 days of selection (200 µg/mL) and confirmation of <i>NOXA</i> KO by Western blotting (panel C), cell densities were adjusted to 4 x 10<sup>5</sup> cells/mL and seeded for CellTiter-Glo2.0 Assay, Caspase-Glo 3/7 Assay and FCA for 2 days. B. Western blot of NOXA in SAFE4501 or <i>NOXA</i> g1 cells. C. Western blot of NOXA in <i>MARCHF5</i>-<i>NOXA</i> DKO cells.

Read the rest (2 more)

D-F. DKO cells were characterized using D. CellTiter-Glo2.0 (viability), <b><i>E</i></b>. Caspase-Glo 3/7 Assay (caspase 3/7 activity), or F. FCA (fitness). Caspase-Glo3/7 luminescence signals were normalized to CellTiter-Glo2.0 signals to normalize for total viable cells.

All data in panels D-F, were further normalized to the SAFE4501-g<i>AAVS1</i> DKO cells to establish the baseline. Statistical differences were calculated using one-way ANOVA with Dunnett’s multiple comparison post-hoc test (n = 3). Error bars, standard error of the mean.</p>

Links

Where it is published

Catalogue records · 1

Topics

Provenance · 1 source records, 13 field assertions
SourceKeyLast seenRaw
UCL Research Data Repositoryoai:figshare.com:article/3404914712 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0
concepts[disease].local:disease:cancermapping · rdr ucl ac ukvocabulary-mapper@1.0.0keywords['Cancer']
concepts[field].anzsrc:field:310706mapping · rdr ucl ac ukvocabulary-mapper@1.0.0keywords['Virology']
concepts[field].anzsrc:field:320211mapping · rdr ucl ac ukvocabulary-mapper@1.0.0keywords['Infectious Diseases']
concepts[field].anzsrc:group:3101mapping · rdr ucl ac ukvocabulary-mapper@1.0.0keywords['Cell Biology']
concepts[field].anzsrc:group:3105mapping · rdr ucl ac ukvocabulary-mapper@1.0.0keywords['Genetics']
concepts[field].local:field:earth-environmentalmapping · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0
concepts[field].local:field:life-sciencesmapping · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0
concepts[field].local:field:medicine-healthmapping · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0
descriptionsource · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0/metadata/dc/description
licensesource · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0/metadata/dc/rights
publication_datesource · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0
titlesource · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0/metadata/dc/title